Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Sanofi : Muzammil Mansuri is Sanofi’s new Executive Committee member

02/05/2016 | 04:30pm US/Eastern
mansuri

Sanofi has announced the appointment of Muzammil “Muz” Mansuri as a new member of the Executive Committee.

Mr. Mansuri joins Sanofi from Gilead Sciences and will take the position of Executive Vice President, Strategy & Business Development. He will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund.

Commenting on the appointment, Olivier Brandicourt, CEO, Sanofi, said: “Muz brings a wealth of experience as a senior executive within the global biopharmaceutical industry.Muz’s deep understanding of business development and strategy of global biopharmaceutical organizations will allow him to contribute significantly to the overall Group strategy and make him a valuable addition to Sanofi and the Executive Committee.”

Mr. Mansuri has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility. From 2007 to 2010, he was Chairman and CEO at CGI Pharmaceuticals. Mr. Mansuri’s most recently was Senior Vice President, Research & Development Strategy and Corporate Development at Gilead Sciences.

Mr. Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D in Organic Chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University.

© Russell Publishing Limited, 2016. All Rights Reserved., source Trade Journals

React to this article
Latest news on GILEAD SCIENCES, INC.
04:30p SANOFI : Muzammil Mansuri is Sanofi’s new Executive Committee member
02/04 GILEAD SCIENCES : Patent Issued for Process for Preparing Dronedarone and Salts ..
02/04 GILEAD SCIENCES : to Release Fourth Quarter and Full Year 2015 Financial Results..
02/04 GILEAD SCIENCES : What's on tap for La Verne this coming year
02/04 GILEAD SCIENCES, INC. : Momentum, Strategy within Today's Market - Analyst Notes..
02/03 GILEAD SCIENCES : Change in Directors or Principal Officers (form 8-K)
02/03DJMerck Revenue and Profit Fall
02/03 Seven $1 billion-plus drugs seen reaching market in 2016
02/02DJGilead Hepatitis C Drugs Beat Sales Views -- Update
02/02DJGilead Hepatitis C Drugs Beat Sales Views
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials